[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@KontraInvest Kontra
Kontra posts on X about $teva, debt, $nvo, $aipa the most. They currently have XXXXX followers and X posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX +28%
- X Month XXXXXX -XX%
- X Months XXXXXXX +336%
- X Year XXXXXXX +240%
Mentions: X #
- X Week X -XX%
- X Month XX -XX%
- X Months XXX +19%
- X Year XXX +24%
Followers: XXXXX #
- X Week XXXXX +0.17%
- X Month XXXXX +1.60%
- X Months XXXXX +13%
- X Year XXXXX +17%
CreatorRank: undefined #
Social Influence
Social category influence finance XXXX% stocks XX% currencies XXXX%
Social topic influence $teva 37.5%, debt 25%, $nvo #147, $aipa 12.5%, cvs 12.5%, $lly 12.5%, emerging markets 12.5%, math 12.5%, if you 12.5%, money XXXX%
Top accounts mentioned or mentioned by @preseidentmusk @futileturtle
Top assets mentioned Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Novo-Nordisk (NVO) CVS Health Corp (CVS) Eli Lilly and Company (LLY)
Top Social Posts
Top posts by engagements in the last XX hours
"New article up on the blog $AI.PA - link in reply"
X Link 2025-07-23T23:23Z 1814 followers, XXX engagements
"A good day to re-post this $TEVA"
X Link 2025-11-26T14:38Z 1814 followers, XXX engagements
"US GLP-1 Weekly Update (IQVIA w/e Nov 21) 🔥 Record 2.2M total scripts 📈 Zepbound +5% 509k 📈 Wegovy +3.6% 286k 🚀 Starters exploding: 422k (near July peak) Novo crushed it 7k of 11k new starters (vs Lilly 4k) thanks to CVS deal Sub-$150 pricing is here. Volume price fears. $NVO $LLY"
X Link 2025-11-29T10:47Z 1814 followers, XXX engagements
"The market is pricing a funeral for a duopoly king $NVO Everyone is chasing Lilly at 35x earnings while leaving Novo Nordisk for dead at 13x. I get it. The 2026 narrative is ugly. We have patent cliffs in emerging markets "Most-Favored-Nation" pricing cuts in the US and a projected EPS drop of 7%. The chart looks like a crime scene. But lets look at the implied math. At XXX DKK the market is pricing in a -XXXX% annual revenue declinefor the next five years. For a company with a functional duopoly in the biggest health trend of the century That is capitulation math. Im not ignoring the"
X Link 2025-12-07T20:48Z 1814 followers, 23K engagements
"The market loves a good "dead money" narrative. Its lazy. Its easy. And in the case of $TEVA its completely wrong. Most people still think Teva is a zombie generic co. saddled with debt fighting deflation. Theyre looking in the rearview mirror. If you look at the windshield you see a massive repricing event happening in real-time. Here is the setup nobody is talking about: The Catalyst Just Hit: Olanzapine NDA submitted. This isn't a pipe dream. Its a potential $2B franchise entering an uncontested market. Zero competition. No black box. This is the "fiction to nonfiction" moment. The Margin"
X Link 2025-12-12T08:54Z 1814 followers, XXX engagements